Ligand Pharmaceuticals, Inc. (NASDAQ: LGND) reported Q1 EPS of $0.07, $0.09 better than the analyst estimate of ($0.02). Loss from continuing ops was ($0.03). Revenue for the quarter came in at $5.6 million versus the consensus estimate of $8.02 million.

Ligand Pharmaceuticals, Inc. reaffirmed FY2012 guidance.

For earnings history and earnings-related data on Ligand Pharmaceuticals, Inc. (LGND) click here.

Earnings